To overcome this issue, a randomized controlled trial should be performed to evaluate the role of different genetic polymorphism (ALDH2, PNPLA3, TM6SF2) in fibrosis in MASLD patients with mild-moderate alcohol consumption. Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.